The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get early access to Argenx’ efgartigimod while it reviews the marketing application for the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive opinion on efgartigimod to be included in the Early Access to
Month: May 2022
Innovations in cancer immunotherapy have achieved clinical success by considerably increasing the survival rate of patients undergoing cancer treatment. However, there still exists an unmet medical need due to the low response rate to checkpoint inhibitors caused by the low immune reactivity of cancer cells in “cold” tumors. In their efforts to turn “cold” tumors
Preparation and FACS of hPBMCs Leukocytes were isolated from whole blood by density gradient centrifugation using Ficoll-Paque (Sigma-Aldrich). If not used immediately, cells were cryopreserved in fetal bovine serum (FBS) + 10% DMSO (Sigma-Aldrich). Prior to fluorescence-activated cell sorting (FACS), cells were thawed, resuspended in 1x PBS + 2% FBS and stained with an fluorescein isothiocyanate-conjugated mouse anti-human CD45
Built on the emerging ecosystems of Web3 and blockchain, decentralized autonomous organizations (DAOs) allow communities to collectively fund and advance biotech research. The majority of biotech companies are highly centralized with much of the data siloed away in their proprietary databases. Companies have no incentives to openly share this data, which slows down progress in
The injection is given in combination with chemotherapy and administered once every three weeks Merck & Co – known as MSD outside the US and Canada – has received a recommendation from The National Institute for Health and Care Excellence (NICE) for its new injectable treatment, Keytruda, with chemotherapy in adults with a rare form
A major study has revealed the “global collateral damage” caused by the disruption to cardiac services from the COVID-19 pandemic. The researchers warn that problems with heart health will “…continue to accrue unless mitigation strategies are speedily implemented”. In the two years from December 2019, when health systems around the world were under extreme pressure
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring
More than 1 million United States youth aged 14 to 17 years old in 2017 became new daily tobacco users within two years. By 2019, more than three quarters of these youths were vaping e-cigarettes daily. More than 1 million United States youth aged 14 to 17 years old in 2017 became new daily tobacco
Ethial statement All experiments were approved by the Ethics Committee in Animal Experimentation of Val de Loire (CEEA Vdl) (certificate of authorisation to experiment on living animals APAFIS number 10237-201706151202940v3). The CEEA vdl is registered by the National Committee ‘Comité National de Réflexion Ethique sur l’Expérimentation Animale’ under the number 19. All experiments were performed
U.S. company CorePath Laboratories is partnering with U.K. diagnostics firm Cizzle Biotechnology on an early-stage lung cancer test for the U.S. Lung cancer is the leading cause of cancer deaths in the U.S., making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate
Approval provides another step forward in transforming multiple myeloma outcomes and eliminating the disease The European Commission (EC) has approved Janssen’s CAR-T therapy, Carvykti, for adults with heavily pre-treated, relapsed and refractory multiple myeloma, marking the treatment’s first approval outside of the US. Carvykti – also known as ciltacabtagene autoleucel or cilta-cel – has been
If you’ve ever wondered whether changing your mind is the best decision, then you should be reassured that your chances of success are better if you do, according to University of Queensland research. Whether or not changes of mind are behaviorally beneficial has been the focus of a special review by cognitive neuroscientists, Professor Jason
Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen. However, new data due to be presented at ASCO suggest that could be changing. In a phase 2 trial, adagrasib achieved an overall response rate of 43% in 112 patients with
The days of heart transplant survivors undergoing invasive biopsies could soon be over after a new MRI technique has proven to be safe and effective; reducing complications and hospital admissions. The days of heart transplant survivors undergoing invasive biopsies could soon be over after a new MRI technique has proven to be safe and effective;
A hospital is made up of various units that work together to provide exemplary patient care. Some of the units involved include surgical suits, emergency areas, diagnostic imaging departments, critical care units, newborn intensive care areas, and laboratories. The design of a health facility is guided by its primary functions, which include research, inpatient and
U.S. biotech company HotSpot Therapeutics, Inc. is looking to increase its drug development and discovery efforts by partnering with Indian data and digital insights company Excelra. HotSpot discovers and develops small molecule allosteric therapies for the treatment of cancer and autoimmune diseases. What are allosteric therapies? In the journal ACS Medicinal Chemistry Letters, Ahmed F.
Initial group of patients have received Saphnelo in a phase 3 trial evaluating lupus nephritis Following its phase 2 proof of concept trial, Saphnelo – also know as anifrolumab – has been provided to patients as part of the critical IRIS phase 3 clinical trial to treat lupus nephritis (LN). As many as 60% of
Smoking is among the most insidiously deadly of habits, harming both the one who smokes and those who are exposed to secondhand smoking. Chronic diseases such as obstructive lung disease and some common forms of lung cancer are far more common in smokers and those inhaling second-hand smoke, than in non-smokers. Study: Risk factors for
Accelerating the Discovery, Translation & Large-Scale Manufacturing of Exosomes & EVs With 3 days of unrivaled content and two dedicated tracks, this year’s summit will be putting the spotlight on cutting-edge strategies from discovery, translation, and clinical development of modified and unmodified exosomes and EVs, to accelerate this emerging field forward. Built with biopharmaceutical industry insights, this in-person conference will delve
Tokyo, Japan – Researchers from Tokyo Metropolitan University have developed a new carbon capture system which removes carbon dioxide directly from the atmosphere with unprecedented performance. Isophorone diamine (IPDA) in a “liquid-solid phase separation” system was found to remove carbon dioxide at the low concentrations contained in the atmosphere with 99% efficiency. The compound is
- 1
- 2
- 3
- …
- 10
- Next Page »